[HTML][HTML] Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents

Q Chen, B Yang, X Liu, XD Zhang, L Zhang, T Liu - Theranostics, 2022 - ncbi.nlm.nih.gov
The histone acetyltransferases CBP and p300, often referred to as CBP/p300 due to their
sequence homology and functional overlap and co-operation, are emerging as critical …

CBP/p300: critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers

AR Waddell, H Huang, D Liao - Cancers, 2021 - mdpi.com
Simple Summary The CREB-binding protein (CBP) and p300 are paralogous lysine
acetyltransferases that serve as critical co-activators for transcription factors involved in …

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy

ZQ Wang, ZC Zhang, YY Wu, YN Pi, SH Lou… - Signal transduction and …, 2023 - nature.com
BET proteins, which influence gene expression and contribute to the development of cancer,
are epigenetic interpreters. Thus, BET inhibitors represent a novel form of epigenetic …

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

L Feng, G Wang, Y Chen, G He, B Liu… - Medicinal research …, 2022 - Wiley Online Library
Abstract Bromodomain‐containing protein 4 (BRD4), as the most studied member of the
bromodomain and extra‐terminal (BET) family, is a chromatin reader protein interpreting …

Pharmacological inhibition of CBP/p300 blocks estrogen receptor alpha (ERα) function through suppressing enhancer H3K27 acetylation in luminal breast cancer

A Waddell, I Mahmud, H Ding, Z Huo, D Liao - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer is the most common cancer in women, affecting 1 in 20
women globally. Breast cancer is divided into four subtypes: luminal A, luminal B, HER2 …

The role of protein acetylation in carcinogenesis and targeted drug discovery

J Yang, C Song, X Zhan - Frontiers in Endocrinology, 2022 - frontiersin.org
Protein acetylation is a reversible post-translational modification, and is involved in many
biological processes in cells, such as transcriptional regulation, DNA damage repair, and …

Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets

H Qian, M Zhu, X Tan, Y Zhang, X Liu, L Yang - Cell Death Discovery, 2023 - nature.com
Transcriptional super-enhancers and the BET bromodomain protein BRD4 are emerging as
critical drivers of tumorigenesis and therapeutic targets. Characterized by substantial …

Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma

W Wei, Z Song, M Chiba, W Wu, S Jeong, JP Zhang… - Leukemia, 2023 - nature.com
Anaplastic large cell lymphoma (ALCL) and classical Hodgkin lymphoma (HL) share a
similar cytological and high surface expression of CD30, and novel therapeutic strategies …

Novel berberine derivatives as p300 histone acetyltransferase inhibitors in combination treatment for breast cancer

R Lai, Z Lin, C Yang, L Hai, Z Yang, L Guo… - European Journal of …, 2024 - Elsevier
Adenoviral E1A binding protein p300 (EP300 or p300) and its similar paralog, cyclic-AMP
response element binding protein (CBP), are important histone acetyltransferases (HAT) …

Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy

YC Duan, SJ Zhang, XJ Shi, LF Jin, T Yu… - European Journal of …, 2021 - Elsevier
Abnormal epigenetics is a critical hallmark of human cancers. Anticancer drug discovery
directed at histone epigenetic modulators has gained impressive advances with six drugs …